Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0000685

Letrozole

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C17H11N5
Numéro CAS:
112809-51-5
Poids moléculaire :
285.30
Numéro MDL:
MFCD00866241
Code UNSPSC :
41116107
ID de substance PubChem :
329831096
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

letrozole

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3

InChI

1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H

Clé InChI

HPJKCIUCZWXJDR-UHFFFAOYSA-N

Informations sur le gène

human ... CYP19A1(1588)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Letrozole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361fd,H373

Classification des risques

Repr. 2 - STOT RE 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Pamela J Goodwin et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(21), 2231-2239 (2014-06-18)
Obesity is associated with poor outcomes in women with operable breast cancer. Lifestyle interventions (LIs) that help women reduce their weight may improve outcomes. We conducted a multicenter randomized trial comparing mail-based delivery of general health information alone or combined
Antonio C Wolff et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(2), 195-202 (2012-12-13)
Recent data showed improvement in progression-free survival (PFS) when adding everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/progression after nonsteroidal aromatase inhibitor (AI) therapy. Here, we report clinical outcomes of combining the mammalian target of rapamycin (mTOR)
Valentina Guarneri et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(10), 1050-1057 (2014-03-05)
This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/human epidermal growth factor receptor 2 (HER2) -negative operable breast cancer. Ninety-two
G Allevi et al.
British journal of cancer, 108(8), 1587-1592 (2013-04-13)
The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response. This single institution
Mothaffar F Rimawi et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(14), 1726-1731 (2013-04-10)
We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique